TPRKB Antibody

What is TPRKB and what cellular functions does it perform?

TPRKB (TP53RK Binding Protein) is a component of the EKC/KEOPS complex involved in tRNA modification, specifically in the formation of threonylcarbamoyl groups on adenosine at position 37 (t6A37) in tRNAs that read codons beginning with adenine . Functionally, TPRKB acts as an allosteric effector that regulates the t6A activity of the complex, though interestingly, it is not itself required for tRNA modification . TPRKB has gained significant research interest due to its complex-independent functions, particularly its relationship with TP53 (p53) and its potential role in cancer cell survival .

What is the relationship between TPRKB and TP53 in cancer biology?

Recent research has identified TPRKB as a significant synthetic lethal vulnerability specifically in TP53-deficient cancers . While TP53 is the most frequently altered gene in human cancer, the mechanisms by which cells adapt to TP53 loss have remained poorly understood. Studies demonstrate that TPRKB knockdown in TP53-deficient cells significantly inhibits proliferation with minimal effect in TP53 wild-type cells . This dependency extends across multiple TP53 alterations including mutations and amplification of MDM2 (the E3-ubiquitin ligase for TP53) . Mechanistically, TP53 indirectly mediates TPRKB degradation, which can be rescued by co-expression of PRPK (another member of the EKC/KEOPS complex) or proteasome inhibition .

What types of TPRKB antibodies are available for research applications?

Research-grade TPRKB antibodies are available in multiple formats to accommodate diverse experimental needs:

These antibodies have been validated through various techniques including antigen-affinity chromatography and recombinant protein targeting .

How should researchers design experiments to study TPRKB dependency in TP53-deficient cancer models?

When investigating TPRKB dependency in TP53-deficient models, researchers should implement a comprehensive experimental framework:

• Cell line selection: Include multiple pairs of isogenic cell lines with and without TP53 alterations. Research has validated this approach using HCT116 TP53+/+ vs. HCT116 TP53-/- models .

• Knockdown methodology: Employ multiple shRNA constructs targeting different regions of TPRKB to control for off-target effects. Based on published research, at least two independent shRNAs should be used .

• Phenotypic assays: Assess proliferation through multiple methodologies (cell counting, metabolic assays, BrdU incorporation), cell cycle progression (propidium iodide staining and flow cytometry), and apoptosis markers .

• In vivo validation: Xenograft models using athymic nude mice have successfully demonstrated the differential effect of TPRKB knockdown in TP53-mutant versus wild-type tumors. Protocol typically involves subcutaneous injection of 1×10^6 cells/side with biweekly tumor measurements over 35-40 days .

• Rescue experiments: Include TP53 reintroduction into null cells to confirm specificity of the dependency relationship .

What are the methodological considerations for investigating TPRKB's role independent of the EKC/KEOPS complex?

To distinguish TPRKB's independent functions from its role in the EKC/KEOPS complex:

• Comparative knockdown studies: Systematically knockdown other EKC/KEOPS complex members (LAGE3, OSGEP, TP53RK) and compare phenotypic outcomes to TPRKB knockdown. Published research demonstrates that depletion of other complex members exhibits TP53-independent effects, supporting complex-independent functions of TPRKB .

• Domain mutation analysis: Create constructs with mutations in domains responsible for EKC/KEOPS complex interaction while preserving other functional domains.

• Co-immunoprecipitation assays: Use TPRKB antibodies to identify novel interaction partners outside the established complex members.

• Temporal analysis: Examine TPRKB degradation dynamics in relation to TP53 status, PRPK expression, and proteasome inhibition .

How can CRISPR-Cas9 technology be optimized for TPRKB functional studies?

For CRISPR-Cas9 targeting of TPRKB:

• Guide RNA selection: Multiple validated gRNA sequences designed by the Feng Zhang laboratory at the Broad Institute are available specifically for the Tprkb gene with minimal off-target risk . These sequences were designed following criteria detailed in Sanjana et al. (2014) .

• Targeting strategy: Target conserved exons to ensure knockout of all potential splice variants. For partial function studies, consider targeting specific domains.

• Validation protocols: Confirm knockout at protein level using validated TPRKB antibodies in Western blotting applications, as gene editing can sometimes result in truncated but partially functional proteins.

• Controls: Include non-targeting gRNAs and rescue experiments with TPRKB cDNA constructs resistant to the guide RNA targeting.

What criteria should guide selection of the appropriate TPRKB antibody for specific research applications?

When selecting TPRKB antibodies, consider:

• Application compatibility: Different antibodies demonstrate varying efficacy across applications. For example, antibody ABIN2856432 is validated for WB, IHC(p), IF, and ICC, while ABIN526388 is optimized for WB and ELISA .

• Epitope specificity: Some antibodies target specific amino acid regions of TPRKB. For instance, monoclonal antibody 3F6 targets AA 66-175 , while other antibodies target AA 35-84 regions. When studying interaction with PRPK or other partners, select antibodies whose epitopes do not overlap with binding domains.

• Species reactivity: Available antibodies vary in cross-reactivity. Some are specific to human TPRKB while others recognize multiple species including human, monkey, rat, mouse, and others .

• Clonality considerations: Polyclonal antibodies provide broader epitope recognition but potentially higher background, while monoclonal antibodies offer higher specificity for defined epitopes.

• Validation data: Review provided validation data specific to your intended application.

What validation steps should be implemented when using TPRKB antibodies in cancer research?

A robust validation framework includes:

• Positive and negative controls:

  • Positive: Cell lines with confirmed TPRKB expression (e.g., TP53-mutant cancer cell lines)

  • Negative: Cells with TPRKB knockdown or knockout (generated via siRNA or CRISPR)

• Antibody specificity confirmation:

  • Western blot should show a single band at approximately 20 kDa (TPRKB's molecular weight)

  • For immunohistochemistry, include peptide competition assays

  • Comparative analysis with multiple antibodies targeting different epitopes

• Technical validation:

  • Optimize antibody concentration through titration experiments

  • For IHC/IF, implement stringent controls for secondary antibody non-specific binding

  • Validate fixation and antigen retrieval methods for immunohistochemistry

• Cross-validation approaches:

  • Correlate protein expression detected by antibody with mRNA levels

  • Compare results across multiple detection methods (e.g., WB, IHC, and IF)

How should researchers interpret conflicting results when studying TPRKB in different cancer models?

When encountering discrepancies in TPRKB studies across cancer models:

• Assess TP53 status rigorously: Confirm TP53 mutation status through sequencing rather than relying on database information. Published research demonstrates that TPRKB dependency is closely linked to functional TP53 status rather than simply genetic alterations .

• Consider MDM2 amplification: Cell lines with wild-type TP53 but amplified MDM2 (which negatively regulates TP53) also show sensitivity to TPRKB knockdown . Evaluate MDM2 expression levels when interpreting unexpected results.

• Evaluate EKC/KEOPS complex member expression: The interaction between TPRKB and PRPK affects TPRKB stability. Variations in PRPK expression across models may explain differential dependency patterns .

• Assess experimental time points: The synthetic lethal effect may have different kinetics across cell models. Implement time-course experiments to capture potential temporal differences in TPRKB dependency.

• Analyze off-target effects: When using RNAi approaches, implement multiple targeting sequences and validate specificity through rescue experiments.

What are common technical challenges when using TPRKB antibodies in immunohistochemistry and how can they be addressed?

Common challenges and solutions include:

• Inconsistent staining patterns:

  • Challenge: Variable staining intensity across tissue samples

  • Solution: Standardize fixation protocols (duration, fixative composition) and implement automated staining platforms

• High background staining:

  • Challenge: Non-specific binding, particularly in necrotic tissue regions

  • Solution: Optimize blocking conditions (increasing blocking agent concentration, extending blocking time) and implement more stringent washing procedures

• Epitope masking:

  • Challenge: Formalin fixation can cross-link proteins and mask epitopes

  • Solution: Compare multiple antigen retrieval methods (heat-induced vs. enzymatic, different pH buffers) and select the optimal method for specific TPRKB antibodies

• Specificity validation:

  • Challenge: Confirming staining represents true TPRKB expression

  • Solution: Compare staining patterns with known TPRKB expression patterns; include tissues from TPRKB knockout models as negative controls

• Quantification challenges:

  • Challenge: Objective quantification of staining intensity

  • Solution: Implement digital pathology approaches with validated algorithms for intensity scoring

By addressing these methodological considerations, researchers can more effectively utilize TPRKB antibodies for investigating this protein's role in cancer biology and its potential as a therapeutic target for TP53-altered cancers.

How might TPRKB be exploited as a therapeutic target in TP53-mutant cancers?

Based on the synthetic lethality relationship between TPRKB and mutant TP53, several therapeutic strategies warrant investigation:

• Small molecule inhibitor development: Design inhibitors that specifically target TPRKB's catalytic or protein-interaction domains. Consider structure-based drug design approaches based on available structural information about TPRKB.

• Degrader approaches: Proteolysis-targeting chimeras (PROTACs) or molecular glue degraders could be developed to induce TPRKB degradation. Search result identifies that Pom-beads pulled down TPRKB and TPRKB binding proteins, suggesting potential approaches for targeted degradation.

• Combination therapies: Explore combinations of TPRKB inhibition with standard chemotherapies or targeted therapies currently used in TP53-mutant cancers to identify synergistic interactions.

• Biomarker development: Develop antibody-based assays to predict and monitor response to TPRKB-targeting therapies, stratifying patients based on TPRKB expression levels and TP53 status.

• Delivery strategies: For RNA interference-based approaches targeting TPRKB, investigate nanoparticle or lipid-based delivery systems to enhance delivery to tumor cells while minimizing off-target effects.

What are the most promising techniques for studying TPRKB protein-protein interactions in living cells?

Advanced methodologies for investigating TPRKB interactions include:

• Proximity labeling techniques: BioID or APEX2 fusion proteins with TPRKB can identify proteins in close proximity within living cells, potentially revealing novel interaction partners beyond the known EKC/KEOPS complex.

• FRET/BRET approaches: Fluorescence or bioluminescence resonance energy transfer techniques using fluorescently tagged TPRKB and potential binding partners can confirm direct interactions and provide spatial information in living cells.

• Live-cell single-molecule tracking: By tracking individual molecules of fluorescently labeled TPRKB, researchers can analyze dynamics of interactions with binding partners in real time.

• Split protein complementation assays: Technologies such as BiFC (Bimolecular Fluorescence Complementation) can visualize TPRKB interactions with specific partners in living cells.

• Mass spectrometry-based interactomics: Combining immunoprecipitation using validated TPRKB antibodies with quantitative mass spectrometry provides comprehensive interaction landscapes, particularly when performed under various cellular stresses relevant to cancer.